Q3 Earnings Forecast for MNPR Issued By Leerink Partnrs

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for Monopar Therapeutics in a research report issued to clients and investors on Monday, November 10th. Leerink Partnrs analyst J. Schwartz expects that the company will post earnings per share of ($0.35) for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. Leerink Partnrs also issued estimates for Monopar Therapeutics’ Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.44) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.74) EPS, Q3 2026 earnings at ($1.75) EPS, Q4 2026 earnings at ($2.26) EPS, FY2026 earnings at ($5.28) EPS, FY2027 earnings at ($5.68) EPS, FY2028 earnings at ($2.09) EPS and FY2029 earnings at $2.31 EPS.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.12.

Several other brokerages have also commented on MNPR. Jones Trading upgraded shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 10th. Piper Sandler set a $95.00 price objective on Monopar Therapeutics and gave the company an “overweight” rating in a research note on Thursday, September 25th. BTIG Research upped their target price on Monopar Therapeutics from $87.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Barclays set a $125.00 price target on shares of Monopar Therapeutics and gave the company an “overweight” rating in a research report on Monday, October 13th. Finally, Oppenheimer set a $115.00 price objective on shares of Monopar Therapeutics and gave the stock an “outperform” rating in a report on Thursday, October 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $108.10.

Monopar Therapeutics Stock Performance

Shares of NASDAQ MNPR opened at $83.43 on Wednesday. The stock has a market cap of $514.76 million, a price-to-earnings ratio of -25.05 and a beta of 1.35. The business has a 50 day simple moving average of $75.56 and a 200 day simple moving average of $50.69. Monopar Therapeutics has a 52 week low of $16.25 and a 52 week high of $105.00.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Police & Firemen s Retirement System of New Jersey bought a new stake in Monopar Therapeutics in the 2nd quarter valued at $34,000. AlphaQuest LLC bought a new position in shares of Monopar Therapeutics during the 1st quarter worth about $44,000. JPMorgan Chase & Co. raised its position in shares of Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after buying an additional 1,821 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Monopar Therapeutics during the second quarter valued at about $80,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Monopar Therapeutics in the second quarter valued at about $104,000. Institutional investors own 1.83% of the company’s stock.

Insider Activity at Monopar Therapeutics

In other news, major shareholder Tactic Pharma Llc sold 550,229 shares of the stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $63.61, for a total value of $35,000,066.69. Following the completion of the sale, the insider directly owned 272,026 shares of the company’s stock, valued at approximately $17,303,573.86. This represents a 66.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 20.50% of the stock is currently owned by company insiders.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.